MHRA makes a promotion

Mark Birse becomes group manager, Inspections GMP/GDP

Mark Birse has been appointed as the UK Medicines and Healthcare products Regulatory Agency’s Group Manager, Inspections (Good Manufacturing Practice (GMP)/Good Distribution Practice (GDP)) following the retirement of Bryan Wright retirement at the end of March.

Birse is a chemistry graduate with an MSc in pharmaceutical sciences and he joined the MHRA in 2002. He was previously one of the MHRA’s GMP Operations Managers and was based at the Welwyn Garden City office.

Prior to this, Birse worked in the pharmaceutical industry for over 10 years in a variety of roles including production support and quality assurance and he is also eligible to be named as a Qualified Person under Directive 2001/83/EC.

In his new role, Birse will be based at the MHRA’s London head office.

You may also like

Packaging

Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons

The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory

MHRA report shows agency met targets and closed year in financial surplus

The UK government agency has reported meeting or exceeding every statutory performance target in the 2025/26 financial year, closing in financial surplus while advancing clinical trials reform and AI regulation
Regulatory

MHRA gives guidance to phase out animal testing

The UK regulatory body is aiming to replace animal usage in science by backing developers using non-animal methods and offering early data reviews, with PETA saying innovation "must be adopted or we will be left in the dust"
Regulatory

UK unveils regulatory pathway to bring space-manufactured medicines to market

The UK Space Agency and MHRA have outlined new guidance, case studies and a regulatory sandbox to support companies developing pharmaceuticals in microgravity, aiming to accelerate the path from in-orbit manufacturing to patient access
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory

Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1

Zelluna has secured alignment with the UK’s MHRA on the clinical and regulatory pathway for its TCR-NK therapy ZI-MA4-1, paving the way for a CTA submission by the end of 2025 and first-in-human trials at The Christie and The Royal Marsden in 2026
Subscribe now